222 related articles for article (PubMed ID: 25612951)
1. [Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].
Kongsted P; Sheikh K; Mouritsen LS; Lindberg H; Sengeløv L
Ugeskr Laeger; 2015 Jan; 177(2A):24-5. PubMed ID: 25612951
[TBL] [Abstract][Full Text] [Related]
2. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.
D'Amato G; Rocha Lima C; Mahany JJ; Muro-Cacho C; Haura EB
Lung Cancer; 2004 Jun; 44(3):381-90. PubMed ID: 15140552
[TBL] [Abstract][Full Text] [Related]
3. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
4. [Case of portal venous gas and pneumatosis cystoides intestinalis occurring during chemotherapy for a castration-resistant prostate cancer].
Iwasaki M; Okajima K; Takano T; Misaki H
Hinyokika Kiyo; 2014 Nov; 60(11):575-8. PubMed ID: 25511946
[TBL] [Abstract][Full Text] [Related]
5. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy.
Nesher L; Rolston KV
Clin Infect Dis; 2013 Mar; 56(5):711-7. PubMed ID: 23196957
[TBL] [Abstract][Full Text] [Related]
6. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
7. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
Tsao CK; Galsky MD; Oh WK
Eur Urol; 2016 Nov; 70(5):707-708. PubMed ID: 27417033
[TBL] [Abstract][Full Text] [Related]
9. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
10. Neutropenic enterocolitis after high-dose chemotherapy and autologous stem cell transplantation: incidence, risk factors, and outcome.
Gil L; Poplawski D; Mol A; Nowicki A; Schneider A; Komarnicki M
Transpl Infect Dis; 2013 Feb; 15(1):1-7. PubMed ID: 22862907
[TBL] [Abstract][Full Text] [Related]
11. Neutropenic enterocolitis associated with docetaxel therapy in a patient with breast cancer.
Rolston KV
Clin Adv Hematol Oncol; 2009 Aug; 7(8):527-8. PubMed ID: 19927979
[No Abstract] [Full Text] [Related]
12. Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Detti B; Franceschini D; Saieva C; Di Brina L; Baki M; Meattini I; Di Cataldo V; Pasquetti EM; Furfaro I; Mancuso A; Simontacchi G; Livi L
Cancer Invest; 2014 Nov; 32(9):445-50. PubMed ID: 25259606
[TBL] [Abstract][Full Text] [Related]
13. [Poor outcome neutropenic enterocolitis after treatment with docetaxel in a breast cancer patient].
Cubo T; Padilla D; Villarejo P; López A; Delgado Y P Menéndez M
Rev Esp Enferm Dig; 2007 Aug; 99(8):480-2. PubMed ID: 18020871
[No Abstract] [Full Text] [Related]
14. Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer.
Takahashi M; Kusuhara Y; Mori H; Komori M; Kagawa J; Fukawa T; Yamamoto Y; Yamaguchi K; Fukumori T; Kanayama H
Clin Genitourin Cancer; 2015 Aug; 13(4):e337-e340. PubMed ID: 25770768
[No Abstract] [Full Text] [Related]
15. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
[TBL] [Abstract][Full Text] [Related]
16. Neutropenic enterocolitis: a serious complication during the treatment of acute leukemias.
Wach M; Dmoszynska A; Wasik-Szczepanek E; Pozarowski A; Drop A; Szczepanek D
Ann Hematol; 2004 Aug; 83(8):522-6. PubMed ID: 14658010
[TBL] [Abstract][Full Text] [Related]
17. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
[TBL] [Abstract][Full Text] [Related]
18. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
Bahl A; Masson S; Malik Z; Birtle AJ; Sundar S; Jones RJ; James ND; Mason MD; Kumar S; Bottomley D; Lydon A; Chowdhury S; Wylie J; de Bono JS
BJU Int; 2015 Dec; 116(6):880-7. PubMed ID: 25639506
[TBL] [Abstract][Full Text] [Related]
19. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
